自体CIK细胞免疫疗法治疗中晚期非小细胞肺癌的临床研究

目的观察自体CIK细胞过继性免疫疗法对中晚期非小细胞肺癌患者的临床疗效。方法体外利用抗CD3单抗、IL-2、IFN-γ等细胞因子从患者外周血单个核细胞（PBMC）中诱导扩增CIK细胞，培养11-14d后，分3个疗程回输患者体内，观察患者临床症状改善及生活质量改善状况，并用流式细胞仪检测回输前后患者T细胞亚群和NK细胞变化。结果86例接受自体CIK细胞治疗患者中，PR＋MR为72例，总缓解率为83．72％。治疗前、后肿瘤患者临床症状有明显改善，有显著性差异（P〈0．01）。CIK细胞经培养后细胞总数和CD3、CD56T效应细胞均获得大量增殖，自体回输免疫治疗后，CD3、CD4T细胞和NK细胞比例均显著提高（P〈0．01）。结论从中晚期非小细胞肺癌患者外周血PBMC中可高效扩增CIK细胞，自体回输能显著提高患者免疫功能，改善临床症状，提高生存质量，延长患者生存期。

The Clinical Study on the Therapeutics of Cytokine-induced Killer Cells on the Patients with Advanced Non-small-cell Lung Cancer

Objective To observe the therapy effect of cytokine-induced killer （CIK） in PBMC of patients with advanced non-small-cell lung cancer. Methods CIK cells were induced and amplified from PBMC of 68 NSCLC patients by in vitro incubation with IL-2, IFN-γ, anti-CD3 monoclonal antibody for 11-14 days and then transfused back to patients. The changes of T cell and NK cell of patients before and after CIK cell treatment with FCM were tested. Results After 11-14 days culture, the total number of CIK cells and CD3^＋ , CD56 ^＋ T cells expanded greatly. After being treated with CIK cells, the numbers of CD3, CD4 T cell and NK cells of patients increased significantly （ P 〈 0.01 ）. The clinical symptoms of 86 patients were improved clearly. Conclusion CIK cells may be expanded effectively from patients with advanced NSCLC. The adoptive immunotherapy of auto-immunity of CIK cells can significantly enhance cellular immune function and improve the clinical symptom of patients.